The number of people suffering from type 2 diabetes (T2DM) and obesity around the world has significantly increased during the past several decades due to changes in eating habits and sedentary lifestyle. As much as 86% of people with T2DM are either overweight or obese [1]. Importantly, overweight people with T2DM are more prone to develop liver steatosis. Not surprisingly, this patient group has a very high prevalence of nonalcoholic fatty liver disease (NAFLD) [2]. Today, NAFLD is the most common chronic liver disease (CLD) that affects 20–40% of the global population and 74% of people suffering from obesity [3].
